Richard B Silverman

List of Publications by Year
in descending order

256 papers	8,790 citations	53660 45 h-index	71532 76 g-index

277 all docs	277 docs citations	277 times ranked	7651 citing authors

#	Article	IF	Citations
1	Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS). Scientific Reports, 2022, 12, 1701.	1.6	8
2	NU-9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone. Scientific Reports, 2022, 12, 5383.	1.6	6
3	Rational Design, Synthesis, and Mechanism of (3S,4R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase. Journal of the American Chemical Society, 2022, 144, 5629-5642.	6.6	4
4	Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma. ACS Medicinal Chemistry Letters, 2022, 13, 38-49.	1.3	7
5	Palladium-Catalyzed Î±-Arylation of Cyclic Î²-Dicarbonyl Compounds for the Synthesis of Ca_V1.3 Inhibitors. ACS Omega, 2022, 7, 14252-14263.	1.6	2
6	A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics, 2022, 14, 1036.	2.0	2
7	2-Aminopyridines with a shortened amino sidechain as potent, selective, and highly permeable human neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 69, 116878.	1.4	6
8	Structural and Kinetic Analyses Reveal the Dual Inhibition Modes of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidenyl)-cyclopentane-1-carboxylic Acid (BCF₃). ACS Chemical Biology, 2021, 16, 67-75.	1.6	5
9	Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDPâ€43 pathology. Clinical and Translational Medicine, 2021, 11, e336.	1.7	20
10	Theoretical and Mechanistic Validation of Global Kinetic Parameters of the Inactivation of GABA Aminotransferase by OV329 and CPP-115. ACS Chemical Biology, 2021, 16, 615-630.	1.6	6
11	Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase. Journal of the American Chemical Society, 2021, 143, 8193-8207.	6.6	7
12	Turnover and Inactivation Mechanisms for (S)-3-Amino-4,4-difluorocyclopent-1-enecarboxylic Acid, a Selective Mechanism-Based Inactivator of Human Ornithine Aminotransferase. Journal of the American Chemical Society, 2021, 143, 8689-8703.	6.6	6
13	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. Current Alzheimer Research, 2021, 18, 283-297.	0.7	3
14	OV329, a novel highly potent Î³â€aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdalaâ€kindled rats. Epilepsia, 2021, 62, 3091-3104.	2.6	10
15	Inducible nitric oxide synthase: Regulation, structure, and inhibition. Medicinal Research Reviews, 2020, 40, 158-189.	5.0	397
16	(S)â€4â€•Amino â€5â€phenoxypentanoate designed as a potential selective agonist of the bacterial transcription factor GabR. Protein Science, 2020, 29, 1816-1828.	3.1	3
17	A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of CaV1.3 L-Type Calcium Channels. ACS Chemical Biology, 2020, 15, 2539-2550.	1.6	13
18	Physiological involvement of presynaptic Lâ€type voltageâ€dependent calcium channels in GABA release of cerebellar molecular layer interneurons. Journal of Neurochemistry, 2020, 155, 390-402.	2.1	12

#	Article	IF	Citations
19	A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of Î³-Aminobutyric Acid. Journal of the American Chemical Society, 2020, 142, 4892-4903.	6.6	20
20	First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate. Journal of Medicinal Chemistry, 2020, 63, 4528-4554.	2.9	14
21	Mechanism-Based Design of 3-Amino-4-Halocyclopentenecarboxylic Acids as Inactivators of GABA Aminotransferase. ACS Medicinal Chemistry Letters, 2020, 11, 1949-1955.	1.3	6
22	Mechanism of Inactivation of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic Acid. Journal of the American Chemical Society, 2019, 141, 10711-10721.	6.6	15
23	A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	77
24	Optimization of Bloodâ€“Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. Journal of Medicinal Chemistry, 2019, 62, 2690-2707.	2.9	29
25	Conversion of Quinazoline Modulators from Inhibitors to Activators of Î²-Glucocerebrosidase. Journal of Medicinal Chemistry, 2019, 62, 1218-1230.	2.9	16
26	Î²-Glucocerebrosidase Modulators Promote Dimerization of Î²-Glucocerebrosidase and Reveal an Allosteric Binding Site. Journal of the American Chemical Society, 2018, 140, 5914-5924.	6.6	29
27	Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent Î³-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction. Journal of the American Chemical Society, 2018, 140, 2151-2164.	6.6	53
28	Total Synthesis of Tambromycin Enabled by Indole Câ€“H Functionalization. Organic Letters, 2018, 20, 2369-2373.	2.4	24
29	Design and Mechanism of GABA Aminotransferase Inactivators. Treatments for Epilepsies and Addictions. Chemical Reviews, 2018, 118, 4037-4070.	23.0	50
30	Structural Basis for Isoform Selective Nitric Oxide Synthase Inhibition by Thiophene-2-carboximidamides. Biochemistry, 2018, 57, 6319-6325.	1.2	3
31	Synthesis of (S)-3-Amino-4-(difluoromethylenyl)-cyclopent-1-ene-1-carboxylic Acid (OV329), a Potent Inactivator of Î³-Aminobutyric Acid Aminotransferase. Organic Letters, 2018, 20, 4589-4592.	2.4	11
32	Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 3958-3978.	2.9	28
33	PLP and GABA trigger GabR-mediated transcription regulation in Bacillus subtilis via external aldimine formation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3891-3896.	3.3	26
34	Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker. Journal of Medicinal Chemistry, 2017, 60, 9360-9375.	2.9	11
35	Selective Targeting by a Mechanism-Based Inactivator against Pyridoxal 5â€²-Phosphate-Dependent Enzymes: Mechanisms of Inactivation and Alternative Turnover. Biochemistry, 2017, 56, 4951-4961.	1.2	15
36	Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 7146-7165.	2.9	18

#	Article	IF	Citations
37	Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker. Journal of Medicinal Chemistry, 2016, 59, 4913-4925.	2.9	23
38	Design and Synthesis of Potent Quinazolines as Selective Î²-Glucocerebrosidase Modulators. Journal of Medicinal Chemistry, 2016, 59, 8508-8520.	2.9	16
39	Targeting Bacterial Nitric Oxide Synthase with Aminoquinoline-Based Inhibitors. Biochemistry, 2016, 55, 5587-5594.	1.2	16
40	Regulation of aldosterone secretion by Cav1.3. Scientific Reports, 2016, 6, 24697.	1.6	30
41	Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase. Biochemistry, 2016, 55, 3702-3707.	1.2	39
42	The Sirtuin-2 Inhibitor AK7 Is Neuroprotective in Models of Parkinsonâ€™s Disease but Not Amyotrophic Lateral Sclerosis and Cerebral Ischemia. PLoS ONE, 2015, 10, e0116919.	1.1	106
43	Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. ACS Medicinal Chemistry Letters, 2015, 6, 840-844.	1.3	38
44	Novel 2,4-Disubstituted Pyrimidines as Potent, Selective, and Cell-Permeable Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2015, 58, 1067-1088.	2.9	27
45	Mechanism of Inactivation of Î³-Aminobutyric Acid Aminotransferase by (1S,3S)-3-Amino-4-difluoromethylene-1-cyclopentanoic Acid (CPP-115). Journal of the American Chemical Society, 2015, 137, 2628-2640.	6.6	29
46	Structure-Based Design of Bacterial Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 994-1004.	2.9	15
47	2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity. Journal of Medicinal Chemistry, 2015, 58, 5548-5560.	2.9	23
48	Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase. Biochemistry, 2015, 54, 4075-4082.	1.2	9
49	Nitric Oxide Synthase as a Target for Methicillin-Resistant Staphylococcus aureus. Chemistry and Biology, 2015, 22, 785-792.	6.2	15
50	Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2015, 58, 5942-5949.	2.9	17
51	Mechanistic Studies of Inactivation of Inducible Nitric Oxide Synthase by Amidines. Biochemistry, 2015, 54, 2530-2538.	1.2	9
52	Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by (S)-2-Amino-5-(2-(methylthio)acetimidamido)pentanoic Acid. Journal of the American Chemical Society, 2015, 137, 5980-5989.	6.6	6
53	Design and Mechanism of Tetrahydrothiophene-Based Î³-Aminobutyric Acid Aminotransferase Inactivators. Journal of the American Chemical Society, 2015, 137, 4525-4533.	6.6	17
54	Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 607-611.	1.3	7

#	Article	IF	Citations
55	Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2015, 58, 8694-8712.	2.9	23
56	Mechanism of Inactivation of GABA Aminotransferase by (E)- and (Z)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic Acid. ACS Chemical Biology, 2015, 10, 2087-2098.	1.6	12
57	Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain, 2015, 138, 3221-3237.	3.7	74
58	Synthesis of mevalonate- and fluorinated mevalonate prodrugs and their inÂvitro human plasma stability. European Journal of Medicinal Chemistry, 2015, 90, 448-461.	2.6	11
59	Ornithine Aminotransferase versus GABA Aminotransferase: Implications for the Design of New Anticancer Drugs. Medicinal Research Reviews, 2015, 35, 286-305.	5.0	28
60	nNOS inhibition during profound asphyxia reduces seizure burden and improves survival of striatal phenotypic neurons in preterm fetal sheep. Neuropharmacology, 2014, 83, 62-70.	2.0	20
61	Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. European Journal of Medicinal Chemistry, 2014, 76, 414-426.	2.6	28
62	Accessible Chiral Linker to Enhance Potency and Selectivity of Neuronal Nitric Oxide Synthase Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 56-60.	1.3	13
63	Potent and Selective Double-Headed Thiophene-2-carboximidamide Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma. Journal of Medicinal Chemistry, 2014, 57, 686-700.	2.9	37
64	Structures of human constitutive nitric oxide synthases. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 2667-2674.	2.5	33
65	Treatment of Amyotrophic Lateral Sclerosis: Lessons Learned from Many Failures. ACS Medicinal Chemistry Letters, 2014, 5, 1179-1181.	1.3	6
66	Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. Chemical Society Reviews, 2014, 43, 6814-6838.	18.7	121
67	Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4504-4510.	1.0	7
68	Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5098-5101.	1.0	16
69	Simplified 2-Aminoquinoline-Based Scaffold for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition. Journal of Medicinal Chemistry, 2014, 57, 1513-1530.	2.9	40
70	Nitric Oxide Synthase Inhibitors That Interact with Both Heme Propionate and Tetrahydrobiopterin Show High Isoform Selectivity. Journal of Medicinal Chemistry, 2014, 57, 4382-4396.	2.9	21
71	The Mobility of a Conserved Tyrosine Residue Controls Isoform-Dependent Enzymeâ€“Inhibitor Interactions in Nitric Oxide Synthases. Biochemistry, 2014, 53, 5272-5279.	1.2	19
72	Two continuous coupled assays for ornithine-Î´-aminotransferase. Analytical Biochemistry, 2013, 440, 145-149.	1.1	14

#	Article	IF	Citations
73	A novel synthesis of 1-aryl-3-piperidone derivatives. Tetrahedron Letters, 2013, 54, 573-575.	0.7	8
74	Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2013, 21, 1333-1343.	1.4	14
75	Structural and biological studies on bacterial nitric oxide synthase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18127-18131.	3.3	43
76	Structure-Guided Design of Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2013, 56, 3024-3032.	2.9	25
77	Probing the steric requirements of the Î³-aminobutyric acid aminotransferase active site with fluorinated analogues of vigabatrin. Bioorganic and Medicinal Chemistry, 2013, 21, 903-911.	1.4	15
78	Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. Experimental Neurology, 2013, 250, 282-292.	2.0	23
79	Chiral linkers to improve selectivity of double-headed neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5674-5679.	1.0	10
80	In search of potent and selective inhibitors of neuronal nitric oxide synthase with more simple structures. Bioorganic and Medicinal Chemistry, 2013, 21, 5323-5331.	1.4	7
81	Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers. Journal of Medicinal Chemistry, 2013, 56, 3121-3147.	2.9	121
82	Arylazanylpyrazolone Derivatives as Inhibitors of Mutant Superoxide Dismutase 1 Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2013, 56, 2665-2675.	2.9	17
83	Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. Bioorganic and Medicinal Chemistry, 2013, 21, 4365-4373.	1.4	33
84	Structureâ€“Activity Relationship of N,Nâ€²-Disubstituted Pyrimidinetriones as Ca_V1.3 Calcium Channel-Selective Antagonists for Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2013, 56, 4786-4797.	2.9	28
85	Targeting Nitric Oxide Signaling with nNOS Inhibitors As a Novel Strategy for the Therapy and Prevention of Human Melanoma. Antioxidants and Redox Signaling, 2013, 19, 433-447.	2.5	51
86	Recent Advances Toward Improving the Bioavailability of Neuronal Nitric Oxide Synthase Inhibitors. Current Topics in Medicinal Chemistry, 2013, 13, 803-812.	1.0	7
87	Direct Amination of Î³-Halo-Î²-ketoesters with Anilines. Journal of Organic Chemistry, 2012, 77, 3462-3467.	1.7	6
88	CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nature Communications, 2012, 3, 1146.	5.8	139
89	Selective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics Simulations. Journal of the American Chemical Society, 2012, 134, 11559-11572.	6.6	21
90	(1S, 3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic Acid (CPP-115), a Potent Î³-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Cocaine Addiction. Journal of Medicinal Chemistry, 2012, 55, 357-366.	2.9	43

#	Article	IF	Citations
91	Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase. Bioorganic and Medicinal Chemistry, 2012, 20, 5763-5773.	1.4	15
92	The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntingtonâ€™s Disease Mouse Models. Cell Reports, 2012, 2, 1492-1497.	2.9	174
93	The 2011 E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances: (1S,3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic Acid (CPP-115), a GABA Aminotransferase Inactivator and New Treatment for Drug Addiction and Infantile Spasms. Journal of Medicinal Chemistry, 2012, 55, 567-575.	2.9	32
94	Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS. ACS Medicinal Chemistry Letters, 2012, 3, 584-587.	1.3	17
95	ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives To Block Mutant Superoxide Dismutase 1 (SOD1) Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2012, 55, 515-527.	2.9	43
96	Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorganic and Medicinal Chemistry, 2012, 20, 1029-1045.	1.4	22
97	Intramolecular hydrogen bonding: A potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2012, 20, 2435-2443.	1.4	35
98	Acid-facilitated debenzylation of N-Boc, N-benzyl double protected 2-aminopyridinomethyl pyrrolidine derivatives. Tetrahedron, 2012, 68, 1359-1366.	1.0	14
99	High yielding allylation of a chiral secondary alcohol containing base sensitive functional groups. Tetrahedron Letters, 2012, 53, 1319-1322.	0.7	5
100	Temperature-Dependent Spin Crossover in Neuronal Nitric Oxide Synthase Bound with the Heme-Coordinating Thioether Inhibitors. Journal of the American Chemical Society, 2011, 133, 8326-8334.	6.6	16
101	Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 87-96.	2.3	34
102	Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-Dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2011, 54, 2409-2421.	2.9	40
103	Symmetric Double-Headed Aminopyridines, a Novel Strategy for Potent and Membrane-Permeable Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2011, 54, 2039-2048.	2.9	38
104	Synthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilanyloxy)decanoic acid, a precursor to the unusual amino acid residue of the anticancer agent microsporin B. Tetrahedron Letters, 2011, 52, 5438-5440.	0.7	5
105	Improved Synthesis of Chiral Pyrrolidine Inhibitors and Their Binding Properties to Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2011, 54, 6399-6403.	2.9	8
106	Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorganic and Medicinal Chemistry, 2011, 19, 613-622.	1.4	20
107	Involvement of Neuronal Nitric Oxide Synthase in Ongoing Fetal Brain Injury following Near-Term Rabbit Hypoxia-Ischemia. Developmental Neuroscience, 2011, 33, 288-298.	1.0	20
108	Neuronal Nitric Oxide Synthase Inhibition Prevents Cerebral Palsy following Hypoxia-Ischemia in Fetal Rabbits: Comparison between JI-8 and 7-Nitroindazole. Developmental Neuroscience, 2011, 33, 312-319.	1.0	39

#	Article	IF	Citations
109	An alkoxide anion-triggered tert-butyloxycarbonyl group migration. Mechanism and application. Tetrahedron Letters, 2010, 51, 2536-2538.	0.7	8
110	Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae. Bioorganic and Medicinal Chemistry, 2010, 18, 1124-1134.	1.4	14
111	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels CaV1.3 and CaV1.2. Bioorganic and Medicinal Chemistry, 2010, 18, 3147-3158.	1.4	41
112	Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2010, 18, 6526-6537.	1.4	19
113	Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 554-557.	1.0	27
114	Peripheral but crucial: A hydrophobic pocket (Tyr706, Leu337, and Met336) for potent and selective inhibition of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6258-6261.	1.0	18
115	Probing Ligand-binding Pockets of the Mevalonate Pathway Enzymes from Streptococcus pneumoniae. Journal of Biological Chemistry, 2010, 285, 20654-20663.	1.6	12
116	Unexpected Binding Modes of Nitric Oxide Synthase Inhibitors Effective in the Prevention of a Cerebral Palsy Phenotype in an Animal Model. Journal of the American Chemical Society, 2010, 132, 5437-5442.	6.6	50
117	Chiral Discrimination among Aminotransferases: Inactivation by 4-Amino-4,5-dihydrothiophenecarboxylic Acid. Biochemistry, 2010, 49, 3138-3147.	1.2	12
118	Mechanism of Inactivation of Escherichia coli Aspartate Aminotransferase by (S)-4-Amino-4,5-dihydro-2-furancarboxylic Acid,. Biochemistry, 2010, 49, 10507-10515.	1.2	5
119	Potent, Highly Selective, and Orally Bioavailable Gem-Difluorinated Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Journal of the American Chemical Society, 2010, 132, 14229-14238.	6.6	55
120	Heme-Coordinating Inhibitors of Neuronal Nitric Oxide Synthase. Ironâ^'Thioether Coordination Is Stabilized by Hydrophobic Contacts without Increased Inhibitor Potency. Journal of the American Chemical Society, 2010, 132, 798-806.	6.6	20
121	Role of Zinc in Isoform-Selective Inhibitor Binding to Neuronal Nitric Oxide Synthase,. Biochemistry, 2010, 49, 10803-10810.	1.2	40
122	Exploration of the Active Site of Neuronal Nitric Oxide Synthase by the Design and Synthesis of Pyrrolidinomethyl 2-Aminopyridine Derivatives. Journal of Medicinal Chemistry, 2010, 53, 7804-7824.	2.9	45
123	Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase. Beilstein Journal of Organic Chemistry, 2009, 5, 28.	1.3	11
124	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. Annals of Neurology, 2009, 65, 209-217.	2.8	78
125	Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on bloodâ€“brain barrier penetration. Bioorganic and Medicinal Chemistry, 2009, 17, 7593-7605.	1.4	16
126	Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorganic and Medicinal Chemistry, 2009, 17, 2371-2380.	1.4	38

#	Article	IF	Citations
127	A cellular model for screening neuronal nitric oxide synthase inhibitors. Analytical Biochemistry, 2009, 390, 74-78.	1.1	16
128	Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping. Journal of Medicinal Chemistry, 2009, 52, 779-797.	2.9	86
129	Design of Selective Neuronal Nitric Oxide Synthase Inhibitors for the Prevention and Treatment of Neurodegenerative Diseases. Accounts of Chemical Research, 2009, 42, 439-451.	7.6	118
130	Concise Route to the Chiral Pyrrolidine Core of Selective Inhibitors of Neuronal Nitric Oxide. Organic Letters, 2009, 11, 5194-5197.	2.4	9
131	Crystal Structures of Constitutive Nitric Oxide Synthases in Complex with De Novo Designed Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2060-2066.	2.9	19
132	Hypoxiaâ€“ischemia causes persistent movement deficits in a perinatal rabbit model of cerebral palsy: assessed by a new swim test. International Journal of Developmental Neuroscience, 2009, 27, 549-557.	0.7	29
133	L337H Mutant of Rat Neuronal Nitric Oxide Synthase Resembles Human Neuronal Nitric Oxide Synthase toward Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 4533-4537.	2.9	11
134	From Basic Science to Blockbuster Drug: The Discovery of Lyrica. Angewandte Chemie - International Edition, 2008, 47, 3500-3504.	7.2	139
135	Synthesis and evaluation of novel aromatic substrates and competitive inhibitors of GABA aminotransferase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3122-3125.	1.0	21
136	Revisiting Heme Mechanisms. A Perspective on the Mechanisms of Nitric Oxide Synthase (NOS), Heme Oxygenase (HO), and Cytochrome P450s (CYP450s). Biochemistry, 2008, 47, 2231-2243.	1.2	105
137	Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors. Journal of the American Chemical Society, 2008, 130, 3900-3914.	6.6	101
138	Enantiomers of 4-Amino-3-fluorobutanoic Acid as Substrates for Î³-Aminobutyric Acid Aminotransferase. Conformational Probes for GABA Binding. Biochemistry, 2007, 46, 13819-13828.	1.2	37
139	Inactivation of Escherichia coli <scp>l</scp>-Aspartate Aminotransferase by (S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic Acid Reveals â€œA Tale of Two Mechanismsâ€[,]. Biochemistry, 2007, 46, 10517-10527.	1.2	15
140	Structure-Based Design and Synthesis ofNÏ‰-Nitro-l-Arginine-Containing Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. Displacement of the Heme Structural Water. Journal of Medicinal Chemistry, 2007, 50, 2089-2099.	2.9	29
141	Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A. Tetrahedron, 2007, 63, 6535-6541.	1.0	71
142	Selective l-nitroargininylaminopyrrolidine and l-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 1928-1938.	1.4	24
143	Hydroxyethylene isosteres of selective neuronal nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 6096-6108.	1.4	6
144	Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1651-1654.	1.0	20

#	Article	IF	Citations
145	Fluorinated Conformationally Restricted Î³-Aminobutyric Acid Aminotransferase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 7404-7412.	2.9	50
146	(Â±)-(1S,2R,5S)-5-Amino-2-fluorocyclohex-3-enecarboxylic Acid. A Potent GABA Aminotransferase Inactivator that Irreversibly Inhibits via an Eliminationâ^'Aromatization Pathway. Biochemistry, 2006, 45, 14513-14522.	1.2	16
147	Conformationally Restricted Dipeptide Amides as Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6254-6263.	2.9	22
148	New substrates and inhibitors of Î³-aminobutyric acid aminotransferase containing bioisosteres of the carboxylic acid group: Design, synthesis, and biological activity. Bioorganic and Medicinal Chemistry, 2006, 14, 1331-1338.	1.4	37
149	Syntheses and evaluation of fluorinated conformationally restricted analogues of GABA as potential inhibitors of GABA aminotransferase. Bioorganic and Medicinal Chemistry, 2006, 14, 2242-2252.	1.4	31
150	Design, synthesis, and biological testing of potential heme-coordinating nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 3185-3198.	1.4	20
151	Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. Bioorganic and Medicinal Chemistry, 2006, 14, 3320-3329.	1.4	46
152	Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2006, 14, 3681-3690.	1.4	6
153	Remote protection prevents unwanted cyclizations with 2-aminopyridines. Tetrahedron Letters, 2006, 47, 6113-6115.	0.7	17
154	Selective Neuronal Nitric Oxide Synthase Inhibitors. Current Topics in Medicinal Chemistry, 2005, 5, 603-624.	1.0	60
155	Mechanism of Inactivation of Inducible Nitric Oxide Synthase by Amidines. Irreversible Enzyme Inactivation without Inactivator Modification. Journal of the American Chemical Society, 2005, 127, 858-868.	6.6	47
156	Exploring the Binding Conformations of Bulkier Dipeptide Amide Inhibitors in Constitutive Nitric Oxide Synthasesâ€. Biochemistry, 2005, 44, 15222-15229.	1.2	18
157	Synthesis of Cyclopropane Isosteres of the Antiepilepsy Drug Vigabatrin and Evaluation of their Inhibition of GABA Aminotransferase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 293-301.	2.5	5
158	Structures of Î³-Aminobutyric Acid (GABA) Aminotransferase, a Pyridoxal 5â€²-Phosphate, and [2Fe-2S] Cluster-containing Enzyme, Complexed with Î³-Ethynyl-GABA and with the Antiepilepsy Drug Vigabatrin. Journal of Biological Chemistry, 2004, 279, 363-373.	1.6	129
159	Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. Nature Structural and Molecular Biology, 2004, 11, 54-59.	3.6	75
160	Conformationally-restricted vigabatrin analogs as irreversible and reversible inhibitors of Î³-aminobutyric acid aminotransferase. Bioorganic and Medicinal Chemistry, 2004, 12, 5719-5725.	1.4	15
161	Inactivation of Î³-aminobutyric acid aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid does not proceed by the expected aromatization mechanism. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 203-206.	1.0	12
162	Structures of the Neuronal and Endothelial Nitric Oxide Synthase Heme Domain withd-Nitroarginine-Containing Dipeptide Inhibitors Boundâ€. Biochemistry, 2004, 43, 5181-5187.	1.2	29

#	Article	IF	Citations
163	Mechanistic Crystallography. Mechanism of Inactivation of Î³-Aminobutyric Acid Aminotransferase by (1R,3S,4S)-3-Amino-4-fluorocyclopentane-1-carboxylic Acid As Elucidated by Crystallographyâ€. Biochemistry, 2004, 43, 14057-14063.	1.2	25
164	Potent and Selective Conformationally Restricted Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 703-710.	2.9	29
165	A mechanism for substrate-Induced formation of 6-Hydroxyflavin mononucleotide catalyzed by C30A trimethylamine dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4129-4132.	1.0	8
166	Inactivation of mitochondrial monoamine oxidase B by methylthio-substituted benzylamines. Bioorganic and Medicinal Chemistry, 2003, 11, 4423-4430.	1.4	17
167	Aromatic Reduced Amide Bond Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2003, 46, 1661-1669.	2.9	41
168	Computer Modeling of Selective Regions in the Active Site of Nitric Oxide Synthases:â€‰ Implication for the Design of Isoform-Selective Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 5700-5711.	2.9	69
169	Design, Synthesis, and Biological Activity of a Difluoro-Substituted, Conformationally Rigid Vigabatrin Analogue as a Potent Î³-Aminobutyric Acid Aminotransferase Inhibitor. Journal of Medicinal Chemistry, 2003, 46, 5292-5293.	2.9	165
170	Purification and inactivation of 3-hydroxyanthranilic acid 3,4-dioxygenase from beef liver. International Journal of Biochemistry and Cell Biology, 2003, 35, 1085-1097.	1.2	8
171	Inactivation and Inhibition of Î³-Aminobutyric Acid Aminotransferase by Conformationally Restricted Vigabatrin Analogues. Journal of Medicinal Chemistry, 2002, 45, 4531-4539.	2.9	33
172	Design of a Conformationally Restricted Analogue of the Antiepilepsy Drug Vigabatrin that Directs Its Mechanism of Inactivation of Î³-Aminobutyric Acid Aminotransferase. Journal of the American Chemical Society, 2002, 124, 1620-1624.	6.6	34
173	Solid-Phase, Pd-Catalyzed Silicon-Aryl Carbon Bond Formation. Synthesis of Sansalvamide A Peptide. Organic Letters, 2002, 4, 4171-4174.	2.4	57
174	Reduced Amide Bond Peptidomimetics. (4S)-N-(4-Amino-5-[aminoalkyl]aminopentyl)-Nâ€˜-nitroguanidines, Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2001, 44, 2667-2670.	2.9	66
175	Mild and Selective Sodium Azide Mediated Cleavage ofp-Nitrobenzoic Esters. Organic Letters, 2001, 3, 2477-2479.	2.4	40
176	Synthesis and Evaluation of Dipeptide Amides Containing N^{Ï‰}-Nitroarginine and D-2, 4-Diaminobutyric Acids as Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 233-239.	0.5	6
177	Short, Highly Efficient Syntheses of Protected 3-Azido- and 4-Azidoproline and Their Precursors. Organic Letters, 2001, 3, 2481-2484.	2.4	56
178	Silicon-based aromatic transferring linkers for traceless solid-phase synthesis of aryl-, polyaryl-, and heteroaryl-containing compounds. Tetrahedron, 2001, 57, 5339-5352.	1.0	25
179	Inactivation of monoamine oxidase B by 1-phenylcyclopropylamine. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1757-1760.	1.0	13
180	Mechanism of Nitric Oxide Synthase. Evidence that Direct Hydrogen Atom Abstraction from the Oâ^'H Bond ofNG-Hydroxyarginine Is Not Relevant to the Mechanism. Journal of the American Chemical Society, 2001, 123, 2674-2676.	6.6	60

#	Article	IF	Citations
181	The Multiple Active Enzyme Species of Î³-Aminobutyric Acid Aminotransferase Are Not Isozymes. Archives of Biochemistry and Biophysics, 2000, 374, 248-254.	1.4	16
182	Anomalous Schmidt reaction products of phenylacetic acid and derivatives. Perkin Transactions II RSC, 2000, , 55-59.	1.1	10
183	Traceless Solid-Phase Synthesis of Chiral 3-ArylÎ²-Amino Acid Containing Peptides Using a Side-Chain-TetheredÎ²-Amino Acid Building Block. Organic Letters, 2000, 2, 303-306.	2.4	33
184	ENDOR Spectroscopic Evidence for the Geometry of Binding ofretro-inverso-NÏ‰-Nitroarginine-Containing Dipeptide Amides to Neuronal Nitric Oxide Synthase. Journal of the American Chemical Society, 2000, 122, 7869-7875.	6.6	14
185	Synthesis and Evaluation of Peptidomimetics as Selective Inhibitors and Active Site Probes of Nitric Oxide Synthases. Journal of Medicinal Chemistry, 2000, 43, 2938-2945.	2.9	36
186	Rapid, High-Yield, Solid-Phase Synthesis of the Antitumor Antibiotic Sansalvamide A Using a Side-Chain-Tethered Phenylalanine Building Block. Organic Letters, 2000, 2, 3743-3746.	2.4	44
187	A New Class of Conformationally Rigid Analogues of 4-Amino-5-halopentanoic Acids, Potent Inactivators of Î³-Aminobutyric Acid Aminotransferase. Journal of Medicinal Chemistry, 2000, 43, 706-720.	2.9	114
188	Selective Inhibition of Monoamine Oxidase B by Aminoethyl Substituted Benzyl Ethers. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 15, 11-21.	0.5	1
189	Isolation and characterization of the product of inactivation of Î³-aminobutyric acid aminotransferase by gabaculine. Bioorganic and Medicinal Chemistry, 1999, 7, 1581-1590.	1.4	28
190	Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. Bioorganic and Medicinal Chemistry, 1999, 7, 1941-1951.	1.4	29
191	Mechanism of Inactivation of Î³-Aminobutyric Acid Aminotransferase by (S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic Acid. Journal of the American Chemical Society, 1999, 121, 7751-7759.	6.6	17
192	Mechanistic Studies of the Inactivation of Inducible Nitric Oxide Synthase byN5-(1-Iminoethyl)-l-ornithine (l-NIO). Journal of the American Chemical Society, 1999, 121, 903-916.	6.6	27
193	Inhibition and Substrate Activity of Conformationally Rigid Vigabatrin Analogues with Î³-Aminobutyric Acid Aminotransferase. Journal of Medicinal Chemistry, 1999, 42, 4725-4728.	2.9	37
194	Efficient Solid-Phase Synthesis of Compounds Containing Phenylalanine and Its Derivatives via Side-Chain Attachment to the Polymer Support. Journal of the American Chemical Society, 1999, 121, 8407-8408.	6.6	34
195	NÏ‰-Nitroarginine-Containing Dipeptide Amides. Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry, 1999, 42, 3147-3153.	2.9	74
196	An Aromatization Mechanism of Inactivation of Î³-Aminobutyric Acid Aminotransferase for the Antibioticl-Cycloserine. Journal of the American Chemical Society, 1998, 120, 2256-2267.	6.6	41
197	Monoamine Oxidase B-Catalyzed Reactions of cis- and trans-5-Aminomethyl-3-(4-Methoxyphenyl)dihydrofuran-2(3H)-ones. Evidence for a Reversible Redox Reaction. Journal of the American Chemical Society, 1998, 120, 10583-10587.	6.6	5
198	Effect of The Locus of The Oxygen Atom in Amino Ethers on the Inactivation of Monoamine Oxidase B. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 31-39.	0.5	4

#	Article	IF	Citations
199	Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by NÏ‰-Allyl-l-Arginine. Journal of the American Chemical Society, 1997, 119, 10888-10902.	6.6	27
200	Potent and Selective Inhibition of Neuronal Nitric Oxide Synthase byNÏ‰-Propyl-l-arginine. Journal of Medicinal Chemistry, 1997, 40, 3869-3870.	2.9	185
201	4-Substituted Cubylcarbinylamines:â€‰ A New Class of Mechanism-Based Monoamine Oxidase B Inactivators. Journal of Medicinal Chemistry, 1997, 40, 1165-1168.	2.9	14
202	Identification of the Active Site Cysteine in Bovine Liver Monoamine Oxidase B. Journal of the American Chemical Society, 1997, 119, 6690-6691.	6.6	42
203	Selective Inhibition of Neuronal Nitric Oxide Synthase byNÏ‰-Nitroarginine- and Phenylalanine-Containing Dipeptides and Dipeptide Esters. Journal of Medicinal Chemistry, 1997, 40, 2813-2817.	2.9	43
204	Inactivation of monoamine oxidase B by benzyl 1-(aminomethyl)cyclopropane-1-carboxylate. Bioorganic and Medicinal Chemistry, 1997, 5, 297-304.	1.4	11
205	Unusual Mechanistic Difference in the Inactivation of Î³-Aminobutyric Acid Aminotransferase by (E)- and (Z)-4-Amino-6-fluoro-5-hexenoic Acid. Journal of the American Chemical Society, 1996, 118, 1253-1261.	6.6	29
206	Mechanisms of Inactivation of Î³-Aminobutyric Acid Aminotransferase by 4-Amino-5-fluoro-5-hexenoic Acid. Journal of the American Chemical Society, 1996, 118, 1241-1252.	6.6	31
207	3-substituted alanines inactivate Î³-aminobutyric acid aminotransferase by the same mechanism as do 4-amino-5-halopentanoic acid analogues. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 143-146.	1.0	2
208	Inactivation of Î³-aminobutyric acid aminotransferase by (Z)-4-amino-6-fluoro-5-hexenoic acid: Identification of an active site residue. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1319-1322.	1.0	2
209	Mechanism-based inactivation of Î³-aminobutyric acid aminotransferase by 3-amino-4-fluorobutanoic acid. Bioorganic and Medicinal Chemistry, 1996, 4, 1521-1535.	1.4	4
210	Inactivation of Î³-aminobutyric acid aminotransferase by l-3-chloroalanine hydroxamate. Bioorganic and Medicinal Chemistry, 1995, 3, 11-18.	1.4	6
211	Sar Studies of Fluorine-Substituted Benzylamines and Substituted 2-Phenylethylamines as Substrates and Inactivators of Monoamine Oxidase B. Journal of Enzyme Inhibition and Medicinal Chemistry, 1995, 9, 203-215.	0.5	12
212	[10] Mechanism-based enzyme inactivators. Methods in Enzymology, 1995, 249, 240-283.	0.4	306
213	Radical Ideas about Monoamine Oxidase. Accounts of Chemical Research, 1995, 28, 335-342.	7.6	252
214	Monoamine oxidase-catalyzed oxidative decarboxylation of cis- and trans-5-aminomethyl-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one. Evidence for the intermediacy of an .alpha.-radical. Journal of the American Chemical Society, 1995, 117, 12895-12896.	6.6	13
215	Synthesis ofN-Carbobenzoxy-N,N-acetals. Synthetic Communications, 1993, 23, 1467-1471.	1.1	6
216	Mechanism-based enzyme inactivation via a diactivated cyclopropane intermediate. Journal of the American Chemical Society, 1993, 115, 2982-2983.	6.6	18

#	Article	IF	Citations
217	The Anti-Ulcer Drug Ranitidine Hydrochloride and its Synthetic Intermediates are Inactivators of Monoamine Oxidase-B. Journal of Enzyme Inhibition and Medicinal Chemistry, 1993, 7, 43-45.	0.5	0
218	Î²-Lactams: A New Class of Conformationally-Rigid Inhibitors of Î³-Aminobutyric Acid Aminotransferase. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 125-129.	0.5	6
219	Inactivation of Î³-Aminobutyric Acid Aminotransferase by Various Amine Buffers. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 195-199.	0.5	6
220	4-(Aminomethyl)-1-Aryl-2-Pyrrolidinones, A New Class of Monoamine Oxidase B Inactivators. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 223-231.	0.5	12
221	Î±-Amino acid analogues as mechanism-based inactivators of Î³-aminobutyric acid aminotransferase. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 1371-1374.	1.0	4
222	3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Research, 1992, 11, 103-110.	0.8	91
223	4-(Oxoalkyl)-Substituted Gaba Analogues as Inactivators and Substrates of Gaba Aminotransferase. Journal of Enzyme Inhibition and Medicinal Chemistry, 1991, 5, 199-205.	0.5	3
224	Mechanisms of inactivation of .gamma.-aminobutyric acid aminotransferase by the antiepilepsy drug .gamma.-vinyl GABA (vigabatrin). Journal of the American Chemical Society, 1991, 113, 9341-9349.	6.6	96
225	Mechanism of inactivation of .gamma.-aminobutyric acid aminotransferase by 4-amino-5-hexynoic acid (.gamma.-ethynyl GABA). Journal of the American Chemical Society, 1991, 113, 9329-9340.	6.6	28
226	The use of mechanism-based inactivators to probe the mechanism of monoamine oxidase. Biochemical Society Transactions, 1991, 19, 201-206.	1.6	27
227	3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. Journal of Medicinal Chemistry, 1991, 34, 2295-2298.	2.9	95
228	Chemoenzymatic Synthesis of (R)- and (S)-4-Amino-3-Methylbutanoic Acids. Synthetic Communications, 1990, 20, 159-166.	1.1	23
229	Effect ofN-Ethylmaleimide on Beef and Rat Liver Vitamin K₁Epoxide Reductase. Journal of Enzyme Inhibition and Medicinal Chemistry, 1990, 3, 289-294.	0.5	2
230	Mechanism of inactivation of monoamine oxidase B by (aminomethyl)trimethylsilane. Journal of the American Chemical Society, 1990, 112, 4499-4507.	6.6	29
231	Synthesis of 2-Substituted-3-Phytyl-1,4-naphthoquinone Epoxides. Synthetic Communications, 1990, 20, 431-438.	1.1	5
232	A Convenient Synthesis of 3-Alkyl-4-aminobutanoic Acids. Synthesis, 1989, 1989, 953-955.	1.2	44
233	Design of potential anticonvulsant agents: mechanistic classification of GABA aminotransferase inactivators. Journal of Medicinal Chemistry, 1989, 32, 2413-2421.	2.9	79
234	Inactivation of .gamma.-aminobutyric acid aminotransferase by (Z)-4-amino-2-fluorobut-2-enoic acid. Biochemistry, 1988, 27, 3285-3289.	1.2	18

#	Article	IF	Citations
235	Mechanism of inactivation of Î³-aminobutyric acid aminotransferase by (S,E) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 747 Td ()-[illegible] 942-946.	1.0	17
236	The Potential Use of Mechanism-Based Enzyme Inactivators in Medicine. Journal of Enzyme Inhibition and Medicinal Chemistry, 1988, 2, 73-90.	0.5	42
237	Identification of the amino acid bound to the labile adduct formed during inactivation of monoamine oxidase by 1-phenylcyclopropylamine. Biochemical and Biophysical Research Communications, 1986, 135, 154-159.	1.0	35
238	Mechanism of inactivation of .gamma.-aminobutyrate aminotransferase by 4-amino-5-fluoropentanoic acid. First example of an enamine mechanism for a .gamma.-amino acid with a partition ratio of 0. Biochemistry, 1986, 25, 6817-6820.	1.2	44
239	4-Amino-2-(substituted methyl)-2-butenoic acids: substrates and potent inhibitors of .gamma.-aminobutyric acid aminotransferase. Journal of Medicinal Chemistry, 1986, 29, 764-770.	2.9	21
240	Inactivation of .gamma.-aminobutyric acid aminotransferase by (S,E)-4-amino-5-fluoropent-2-enoic acid and effect on the enzyme of (E)-3-(1-aminocyclopropyl)-2-propenoic acid. Journal of Medicinal Chemistry, 1986, 29, 1840-1846.	2.9	24
241	An Efficient Synthesis of 3-Amino-4-Fluorobutanoic Acid, an Inactivator of GABA Transaminase. Synthetic Communications, 1985, 15, 377-383.	1.1	8
242	Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamine. Biochemistry, 1985, 24, 2128-2138.	1.2	79
243	Revised mechanism for inactivation of mitochondrial monoamine oxidase by N-cyclopropylbenzylamine. Biochemistry, 1985, 24, 6538-6543.	1.2	36
244	The organic chemistry of mechanism-based enzyme inhibition: A chemical approach to drug design. Medicinal Research Reviews, 1984, 4, 415-447.	5.0	37
245	Mechanism-based inactivation of mitochondrial monoamine oxidase by N-(1-methylcyclopropyl)benzylamine. Biochemistry, 1984, 23, 1322-1332.	1.2	65
246	Effect of .alpha.-methylation on inactivation of monoamine oxidase by N-cyclopropylbenzylamine. Biochemistry, 1984, 23, 5206-5213.	1.2	35
247	and effects on brain GABA metabolism of (S)-4-amino-5-fluoropentanoic acid, a mechanism-based inactivator of Î³-aminobutyric acid transaminase. Life Sciences, 1983, 32, 2717-2723.	2.0	7
248	Mechanism of inactivation of .gamma.-aminobutyric acid-.alpha.-ketoglutaric acid aminotransferase by 4-amino-5-halopentanoic acids. Biochemistry, 1981, 20, 1197-1203.	1.2	64
249	Invivo inactivation of Î³-aminobutyric acid-Î±-ketoglutarate transaminase by 4-amino-5-fluoropentanoic acid. Biochemical and Biophysical Research Communications, 1981, 102, 520-523.	1.0	10
250	N-(1-Methyl)cyclopropylbenzylamine: A novel inactivator of mitochondrial monoamine oxidase. Biochemical and Biophysical Research Communications, 1981, 101, 1396-1401.	1.0	34
251	Syntheses of N-[1-2H]- and N-[1-3H]-cyclopropylbenzylamine and [phenyl-14C]-N-cyclopropylbenzylamine. Journal of Labelled Compounds and Radiopharmaceuticals, 1981, 18, 781-790.	0.5	6
252	Syntheses of (S)-5-substituted 4-aminopentanoic acids: a new class of .gamma.-aminobutyric acid transaminase inactivators. Journal of Organic Chemistry, 1980, 45, 815-818.	1.7	127

#	Article	IF	Citations
253	Irreversible inactivation of pig brain Î³-aminobutyric acid-Î±-ketoglutarate transaminase by 4-amino-5-halopentanoic acids. Biochemical and Biophysical Research Communications, 1980, 95, 250-255.	1.0	40
254	Synthesis of [carboxyl -14C] 5 - fluoroorotic acid. Journal of Labelled Compounds and Radiopharmaceuticals, 1979, 16, 361-364.	0.5	2
255	Reaction of diethyl acetonedicarboxylate with nitrosyl chloride. Journal of Heterocyclic Chemistry, 1978, 15, 1519-1520.	1.4	5
256	Mechanism of inactivation of Î³-cystathionase by Î²,Î²,Î²-trifluoroalanine. Biochemistry, 1977, 16, 5515-5520.	1.2	45